A pair of sisters from Wisconsin said the HPV Vaccine that is supposed to prevent cervical cancer instead shut down their ovaries and made them both infertile, according to a claim that headed to a hearing Thursday and Friday in Washington, D.C., federal court.

Madelyne, 20 and Olivia, 19, Meylor allegedly suffered premature ovarian failure after they were vaccinated with Gardasil, a popular vaccine against Human papillomavirus. A certain strain on HPV can cause cervical cancer.

The Meylor sisters claimed the vaccine caused their ovaries to stop producing eggs completely. They also believe the drug also gave them premature menopause, marked by insomnia, night sweats and headaches, according to The Wisconsin State Journal.

"I've always wanted a huge family, but I don't know if that will be possible," Madelyne told the paper.

"People should look into the vaccine more and see if the benefits outweigh the risks," Olivia added.

Both sisters were diagnosed with premature ovarian failure at age 16 and tests for three genetic causes conducted on both women proved negative.

The claim the sisters filed against Merck, who manufactures Gardasil, is the first to reach a hearing through the National Vaccine Injury Compensation Program. It is unclear how long the claim has been waiting to be heard.

Merck released a statement about the case saying it "reviewed the post-licensure reports of POI after administration of Gardasil and has concluded that the evidence does not support a causal relationship to the vaccine."

"The cases have been reported to the U.S. FDA and other regulatory agencies," the statement also said. "There have been no reports of POI in the clinical trials with Gardasil."

The vaccine is recommended by health officials. It is supposed to be administered in three doses to both girls and boys ages 11 and 12 to protect against HPV, a sexually transmitted disease that can cause cervical cancer, throat cancer and genital warts.

There are two vaccines on the market. Gardasil was approved in 2006, while Cervarix was approved in 2009.